Ignite Creation Date:
2025-12-24 @ 2:11 PM
Ignite Modification Date:
2026-01-05 @ 2:23 AM
Study NCT ID:
NCT06709495
Status:
RECRUITING
Last Update Posted:
2025-02-13
First Post:
2024-11-17
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Phase 1/2 Trial to Evaluate the Safety and Efficacy of PEEL-224 in Combination With Vincristine and Temozolomide in Adolescents and Young Adults With Relapsed or Refractory Sarcomas
Sponsor:
David S Shulman, MD
Organization:
Organization Data
Organization:
Class:
OTHER
Study ID:
24-591
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
OTHER
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR_INVESTIGATOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None
Collaborators
Collaborators
| Name | Class | View |
|---|---|---|
| None | INDUSTRY | View |